HITLAB and ENB Therapeutics Partner to Transform Immunotherapy-Resistant Cancers into Clinical Victories
NEW YORK, NY – April 15, 2026 – Every year, thousands of cancer patients on immunotherapy hit a wall: their tumors develop resistance, their treatments stop working, and clinicians face no validated alternatives. Today, HITLAB and ENB Therapeutics announce a partnership designed to change that trajectory. Together, they are converting ENB’s groundbreaking small-molecule therapies–engineered to restore immunotherapy effectiveness–into the clinical and commercial evidence that investment partners and pharmaceutical giants’ demand.
Rather than pursuing incremental validation, HITLAB and ENB are executing a deliberate evidence-generation strategy. This partnership transforms ENB’s clinical data into peer-reviewed publications, investor briefings, and a compelling market narrative–positioning ENB not as a promising clinical stage company, but as a de facto standard for overcoming immunotherapy resistance.
“Immunotherapy resistance represents a $50 billion annual opportunity in oncology–and a tragedy for patients who run out of options. ENB’s science is exceptional, but exceptional science alone doesn’t move the needle in capital markets. HITLAB exists to bridge that gap: we synthesize rigorous evidence that surgeons, oncologists, investors, and pharma executives all recognize and act on. This partnership is about building ENB’s credibility in real time, through the mechanisms that matter most in the market.” – Stan Kachnowski, Chair, HITLAB
The partnership encompasses three core workstreams:
- Evidence Synthesis & Publication: Converting ENB’s clinical dataset into 3-5 peer-reviewed manuscripts, white papers, and commercial briefings that validate efficacy and differentiation across key indications.
- Clinical Validation & Market Feedback: Conducting structured feedback sessions with leading oncologists, hospital networks, and CDxO partners to validate ENB’s clinical value proposition and inform development priorities.
- Strategic Positioning & Investor Engagement: Packaging this evidence into investor-ready narratives for venture capital and pharmaceutical licensing discussions, culminating in a featured presentation at HITLAB’s May 2026 Innovators Summit.
“Our clinical data shows compelling evidence of restored tumor response in patients resistant to standard immunotherapy. But translating that into partnerships with pharma requires a strategic partner who can navigate the evidence standards, publication timelines, and market positioning that matter to investors. HITLAB’s approach–rigorous evidence synthesis combined with strategic market validation–is precisely what a clinical-stage company needs to accelerate from bench to bedside.” Said Sumhayah Jama, President, Co-founder, Chief Scientific Officer at ENB Therapeutics
About HITLAB
HITLAB is a healthcare innovation research and commercialization organization based in New York City. We partner with clinical-stage companies, medtech innovators, and health systems to validate breakthrough technologies, generate market evidence, and accelerate commercialization through rigorous evaluation, strategic positioning, and investor engagement.
About ENB Therapeutics
Share the article:
Learn more about
